逆转录病毒基因组靶向抑制剂-猫眼课题宝

逆转录病毒基因组靶向抑制剂

批准号：

7173294

负责人：

Virendra Nath PANDEY

金额：

$36.86万

依托单位：

UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL

依托单位国家：

美国

项目类别：

财政年份：

1999

资助国家：

美国

项目状态：

已结题

起止时间：

1999-04-01 至 2009-01-31

来源：

https://reporter.nih.gov/project-details/7173294

关键词：

Animal Model Anti-HIV Agents Antiviral Agents Appendix Cell Proliferation Cells Child Class Clinical Conserved Sequence Cultured Cells Data Development Plans Dimerization Drug Delivery Systems Drug Formulations Drug Kinetics Drug or chemical Tissue Distribution Drug resistance Drug usage Evaluation Exhibits Face Fluorescein Fluoresceins Gagging Genetic Genome HIV-1 Human Immune response In Vitro Individual Kinetics Life Cycle Stages Literature Lymphoid Cell Manuscripts Measures Membrane Methods Minority Monitor Mus Numbers Nylons Peptides Peripheral Blood Lymphocyte Peripheral Blood Mononuclear Cell Phase Pliability Progress Reports Property Publications RNA Regulatory Element Reporter Genes Research Research Design Resort Resources Retroviridae Reverse Transcription SCID Mice SCID-hu Mice Safety Staging Tars Therapeutic Therapeutic Index Translations Vertebrates Viral Viral Genome Virus Virus Diseases Woman cytokine cytotoxicity design fluorophore genome sequencing human subject in vivo inhibitor/antagonist mouse model novel nucleotide analog pol genes prevent reconstitution response uptake vector

项目摘要

项目成果

Virendra Nath PANDEY的其他基金

相似基金

相关文献

中文摘要

翻译

点击翻译按钮获取中文摘要

英文摘要

four pages) ............. 6-8 Other Biographical Sketches (Not to exceed four pages for each) ............................................... 9-31 Resources ...................................................................................................................................... 32 Research Plan 33-35 Introductionto Revised Application (Not to exceed 3 pages) ............................................................................................................................... Introduction to Supplemental Application (Notto exceed one page) .................................................................................................................... A. Specific Aims .......................................................................... _ ......................................................................................................... 36-60 B. Background and Significance ...................................................... !...................................................................................................... _._" C. Preliminary Studies/Progress Report/ _ (Items A-D: not to exceed 25 pages*) _K_ Phase I Progress Report (SBIPJSTTR Phase II ONLY) I * SBIR/STTR Phase I: Items A-D limited to 15 pages, t D. Research Design and Methods ............................................ _ ..................................................................................................... E Human Subjects ......................................................................................................................................................................................... Protection of Human Subjects (Required if Item 4 on the Face Page is marked "Yes") Inclusion of Women (Required if Item 4 on the Face Page is marked "Yes") ................................................................................... Inclusion of Minorities (Required if Item 4 on the Face Page is marked "Yes") ................................................................................ Inclusion of Children (Required if Item 4 on the Face Page is marked "Yes") ................................................................................... Data and Safety Monitoring Plan (Required if Item 4 on the Face Page is marked "Yes" anda Phase I, 11,or III clinical roposed trial is proposed ................................................................................................................................................................................ F. Vertebrate Animals ..................................................................................................................................................................................... 61 G, Literature Cited ........................................................................................................................................................................................... H. Consortium/Contractual Arrangements .................................................................................................................................................... I. Consultants ................................................................................................................................................................................................. 68-74 J. Product Development Plan (SBIR/STTR Phase I1and Fast-Track ONLY) ........................................................................................... Checklist ........................................................................................................................................ 75 Check if Appendix (Five collated sets_ No page numbering necessary for Appendix.) Appendix is Included Appendices NOT PERMITTED for Phase I SBIR/S TTR unless specifically solicited, 6 Number of publications and manuscripts accepted for publication (not to exceed 10) Other items (list): PHS 398 (Rev, 510 l) Page 3 Number pages consecutively at the bottom throughout the application. Do _t use suffixes such as 3a, 3b,

期刊论文(17)

专著(0)

科研奖励(0)

会议论文